文献速递肺栓塞与肺血管病

ASK1抑制剂在肺动脉高压临床前模型中阻止疾病进展

ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

本研究在两种肺动脉高压大鼠模型、小鼠右心室压力超负荷模型及细胞模型中,口服给予选择性ASK1抑制剂GS-444217。结果显示GS-444217剂量依赖性降低肺动脉压和右心室肥厚,且在已建立疾病模型中仍有效,并直接减轻心脏纤维化、改善心脏功能。

要点

  • ASK1抑制可减轻肺血管和右心室病理重塑
  • GS-444217在已建立疾病的动物模型中仍显示疗效
  • ASK1抑制直接减少心脏纤维化并改善右心室功能

核心结论

  • ASK1抑制可减轻肺血管和右心室病理重塑,并在啮齿类模型中阻止肺动脉高压进展。
  • 临床前数据首次描述ASK1在肺动脉高压发病机制中的因果作用。

研究设计与样本

  • 在两种肺动脉高压大鼠模型(野百合碱和Sugen/低氧)、肺动脉环缩诱导的小鼠右心室压力超负荷模型及细胞模型中给药。
  • 使用选择性口服ASK1抑制剂GS-444217。

主要发现

  • 口服GS-444217剂量依赖性降低肺动脉压并减轻肺动脉高压模型的右心室肥厚。
  • 疗效与ASK1磷酸化降低、肺动脉肌化减少及右心室纤维化基因表达降低相关。
  • 在已建立疾病的动物模型中给予GS-444217仍观察到疗效。
  • 在孤立性右心室压力超负荷模型中,GS-444217直接减少心脏纤维化并改善心脏功能。
  • 细胞模型中,GS-444217减少腺病毒过表达ASK1诱导的大鼠心肌细胞p38和JNK磷酸化,并减少小鼠心脏成纤维细胞和肺动脉高压患者来源人肺外膜成纤维细胞的活化/迁移。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Progression of pulmonary arterial hypertension (PAH) is associated with pathological remodeling of the pulmonary vasculature and the right ventricle (RV). Oxidative stress drives the remodeling process through activation of MAPKs (mitogen-activated protein kinases), which stimulate apoptosis, inflammation, and fibrosis. OBJECTIVES: We investigated whether pharmacological inhibition of the redox-sensitive apical MAPK, ASK1 (apoptosis signal-regulating kinase 1), can halt the progression of pulmonary vascular and RV remodeling. METHODS: A selective, orally available ASK1 inhibitor, GS-444217, was administered to two preclinical rat models of PAH (monocrotaline and Sugen/hypoxia), a murine model of RV pressure overload induced by pulmonary artery banding, and cellular models. MEASUREMENTS AND MAIN RESULTS: Oral administration of GS-444217 dose dependently reduced pulmonary arterial pressure and reduced RV hypertrophy in PAH models. The therapeutic efficacy of GS-444217 was associated with reduced ASK1 phosphorylation, reduced muscularization of the pulmonary arteries, and reduced fibrotic gene expression in the RV. Importantly, efficacy was observed when GS-444217 was administered to animals with established disease and also directly reduced cardiac fibrosis and improved cardiac function in a model of isolated RV pressure overload. In cellular models, GS-444217 reduced phosphorylation of p38 and JNK (c-Jun N-terminal kinase) induced by adenoviral overexpression of ASK1 in rat cardiomyocytes and reduced activation/migration of primary mouse cardiac fibroblasts and human pulmonary adventitial fibroblasts derived from patients with PAH. CONCLUSIONS: ASK1 inhibition reduced pathological remodeling of the pulmonary vasculature and the right ventricle and halted progression of pulmonary hypertension in rodent models. These preclinical data inform the first description of a causal role of ASK1 in PAH disease pathogenesis.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Budas GR, Boehm M, Kojonazarov B, et al. ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2018. PMID: 28910144. doi:10.1164/rccm.201703-0502OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。